research Drugs and Androgenetic Alopecia: What to look out for
Certain drugs can worsen hair loss in people prone to androgenetic alopecia.
Search
for
Sort by
Research
360-390 / 1000+ results 
research A comprehensive investigation of biochemical status in patients with telogen effluvium: Analysis of Hb, ferritin, vitamin B12 , vitamin D, thyroid function tests, zinc, copper, biotin, and selenium levels
Telogen effluvium is linked to deficiencies in iron, vitamin B12, and thyroid function.
research Report on the 11th National Congress AICPE (Associazione Italiana di Chirurgia Plastica Estetica) Held in Rimini, Italy, 12–14 April 2024
The 11th AICPE Congress in Rimini was a major event in European aesthetic plastic surgery.
research Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
New understanding and treatments for hair loss are improving, but more research is needed.
research 1,314
The convention highlighted the importance of comprehensive patient care and early diagnosis in dermatology.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research Mercury Rising
Eating too much fish can lead to mercury poisoning.
research A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
Monoclonal antibodies are often linked to alopecia areata cases.
research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
LLLT devices for hair loss need more research to define proper guidelines.
research FDA Reports of Alopecia as an Adverse Event to Isotretinoin
Isotretinoin may cause hair loss, especially in women and young adults.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research FDA Approved pediatric antihypertensive agents
FDA-approved medications are important for treating high blood pressure in children, but non-approved ones can be used if needed.
research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
research Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment
Cyclosporine may cause hair loss, so patients need monitoring.
research Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research 484 FDA cleared devices produce inconsistent platelet-rich plasma product
FDA-cleared devices often fail to produce high-quality platelet-rich plasma consistently.
research FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire/Function in Women
Some medications can help increase sexual desire and function in women.
research Novel acne cream seeks FDA approval
A new acne cream effectively reduced acne in trials and awaits FDA approval.
research FDA approves label addition for PDE-5 inhibitor
The FDA approved using Cialis with Proscar for better treatment options.
research FDA vetoes labelling proposals for finasteride, dutasteride
research Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea
Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
research Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss
The FDA struggles to regulate hair loss supplements due to a law allowing unproven claims.